donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GBT Global Blood Therapeutics
66.575
-0.025-0.04%
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Ted W. Love, M.D.President, Chief Executive Officer and Director8.19M----63male04/28/2022
Mr. Jeffrey S. FarrowChief Financial Officer and Principal Accounting Officer2.76M----60male04/28/2022
Ms. Tricia Borga Suvari, Esq.Chief Legal Officer5.93M----61female04/28/2022
Mr. David L. Johnson, C.P.A.Chief Commercial Officer2.75M----53male04/28/2022
Ms. Jung E. ChoiChief Business Officer and Chief Strategy Officer2.73M----52female04/28/2022
Ms. Carrie Krehlik, M.B.A.Chief Human Resources Officer------54female04/28/2022
Ms. Kim Smith-WhitleyExecutive Vice President, Head of Research and Development2.81M----61female04/28/2022
Ms. Nazila HabibizadExecutive Vice President, Operations------59female04/28/2022
Mr. Willie Brown, JrDirector Emeritus308.28K----87male04/28/2022
The Honourable Deval L. PatrickIndependent Director313.28K----65male04/28/2022
Mr. Mark L. PerryLead Independent Director348.28K----66male04/28/2022
Ms. Wendy L. YarnoIndependent Director320.78K----67female04/28/2022
Dr. Glenn F. Pierce, M.D.Independent Director318.28K----66male04/28/2022
Dr. Philip A. Pizzo, M.D.Independent Director310.78K----77male04/28/2022
Ms. Dawn A. SvoronosIndependent Director316.36K----68female04/28/2022
Mr. Scott W. MorrisonIndependent Director333.28K----64male04/28/2022
Dr. Alexis A. Thompson, M.D.Independent Director735.61K----63female04/28/2022
Company Overview More
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
CEO: Love M.D., Ted W.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...